- Home
- ALVO vs IMVT Comparison
ALVO vs IMVT Comparison
Compare ALVO & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVO
- IMVT
- Stock Information
- Founded
- ALVO 2013
- IMVT 2018
- Country
- ALVO Luxembourg
- IMVT United States
- Employees
- ALVO N/A
- IMVT N/A
- Industry
- ALVO Biotechnology: Pharmaceutical Preparations
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALVO Health Care
- IMVT Health Care
- Exchange
- ALVO Nasdaq
- IMVT Nasdaq
- Market Cap
- ALVO 2.5B
- IMVT 2.7B
- IPO Year
- ALVO N/A
- IMVT N/A
- Fundamental
- Price
- ALVO $8.33
- IMVT $17.14
- Analyst Decision
- ALVO
- IMVT Buy
- Analyst Count
- ALVO 0
- IMVT 11
- Target Price
- ALVO N/A
- IMVT $33.88
- AVG Volume (30 Days)
- ALVO 486.2K
- IMVT 1.4M
- Earning Date
- ALVO 08-13-2025
- IMVT 08-11-2025
- Dividend Yield
- ALVO N/A
- IMVT N/A
- EPS Growth
- ALVO N/A
- IMVT N/A
- EPS
- ALVO 0.22
- IMVT N/A
- Revenue
- ALVO $562,478,000.00
- IMVT N/A
- Revenue This Year
- ALVO $33.32
- IMVT N/A
- Revenue Next Year
- ALVO $46.16
- IMVT N/A
- P/E Ratio
- ALVO $37.86
- IMVT N/A
- Revenue Growth
- ALVO 82.19
- IMVT N/A
- 52 Week Low
- ALVO $7.35
- IMVT $12.72
- 52 Week High
- ALVO $13.70
- IMVT $34.47
- Technical
- Relative Strength Index (RSI)
- ALVO 48.09
- IMVT 61.71
- Support Level
- ALVO $7.85
- IMVT $14.47
- Resistance Level
- ALVO $8.12
- IMVT $17.06
- Average True Range (ATR)
- ALVO 0.27
- IMVT 0.65
- MACD
- ALVO 0.01
- IMVT 0.26
- Stochastic Oscillator
- ALVO 39.47
- IMVT 92.71
About ALVO Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.